Results 141 to 150 of about 2,720 (166)
Some of the next articles are maybe not open access.

Imipenem/relebactam pharmacokinetics in critically ill patients supported on extracorporeal membrane oxygenation

Journal of Antimicrobial Chemotherapy
Abstract Background Extracorporeal membrane oxygenation (ECMO) is a life-saving modality but has the potential to alter the pharmacokinetics (PK) of antimicrobials. Imipenem/cilastatin/relebactam is an antibiotic with utility in treating certain multi-drug resistant Gram-negative infections.
Andrew J Fratoni   +4 more
openaire   +2 more sources

Evolution of Imipenem-Relebactam Resistance Following Treatment of Multidrug-Resistant Pseudomonas aeruginosa Pneumonia

Clinical Infectious Diseases, 2022
Daria Van Tyne   +2 more
exaly  

Imipenem/cilastatina/relebactam en infecciones por bacterias gramnegativas

Panorama Actual del Medicamento
Relebactam es un nuevo inhibidor de betalactamasas con estructura no betalactámica, con capacidad para inhibir betalactamasas de tipo A y C, pero no B y D. Sin actividad antibacteriana significativa, la función de relebactam en la combinación con imipenem y cilastatina consiste en restituir la actividad bactericida de imipenem cuando ésta se ve ...
openaire   +1 more source

Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants

Antimicrobial Agents and Chemotherapy, 2020
Maria Nieves Larrosa   +2 more
exaly  

In vitro development of imipenem/relebactam resistance in KPC-producing Klebsiella pneumoniae involves multiple mutations including OmpK36 disruption and KPC modification

International Journal of Antimicrobial Agents, 2023
Concepción Gonzalez-Bello   +2 more
exaly  

Home - About - Disclaimer - Privacy